On Friday, U.S. Sen. Dick Durbin’s office announced legislation to reduce the “monopoly period” of expensive pharmaceuticals when their prices suddenly spike. When new drugs are approved, the U.S. Food and Drug Administration agrees not to review – and therefore approve – cheaper, generic alternatives for a period of five to 12 years.